A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

Efficacy and safety of fuzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: A multi-center, single-arm prospective phase II clinical study (STAMP study)

11 p | 5 | 3

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

9 p | 12 | 1